These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1284 related articles for article (PubMed ID: 29473971)

  • 21. Journey of Von Hippel-Lindau (VHL) E3 ligase in PROTACs design: From VHL ligands to VHL-based degraders.
    Setia N; Almuqdadi HTA; Abid M
    Eur J Med Chem; 2024 Feb; 265():116041. PubMed ID: 38199162
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Proteolysis-targeting chimeras (PROTACs) in cancer therapy.
    Li X; Pu W; Zheng Q; Ai M; Chen S; Peng Y
    Mol Cancer; 2022 Apr; 21(1):99. PubMed ID: 35410300
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Targeted protein degradation: elements of PROTAC design.
    Paiva SL; Crews CM
    Curr Opin Chem Biol; 2019 Jun; 50():111-119. PubMed ID: 31004963
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Targeted protein degradation by PROTACs.
    Neklesa TK; Winkler JD; Crews CM
    Pharmacol Ther; 2017 Jun; 174():138-144. PubMed ID: 28223226
    [TBL] [Abstract][Full Text] [Related]  

  • 25. New Frontiers in the Discovery and Development of PROTACs.
    Barghout SH
    Anticancer Agents Med Chem; 2022 Aug; 22(15):2656-2661. PubMed ID: 35418290
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Proteolysis targeting chimeras (PROTACs) are emerging therapeutics for hematologic malignancies.
    He Y; Khan S; Huo Z; Lv D; Zhang X; Liu X; Yuan Y; Hromas R; Xu M; Zheng G; Zhou D
    J Hematol Oncol; 2020 Jul; 13(1):103. PubMed ID: 32718354
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The impact of E3 ligase choice on PROTAC effectiveness in protein kinase degradation.
    Sobierajski T; Małolepsza J; Pichlak M; Gendaszewska-Darmach E; Błażewska KM
    Drug Discov Today; 2024 Jul; 29(7):104032. PubMed ID: 38789027
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Proteolysis-targeting chimera (PROTAC) delivery system: advancing protein degraders towards clinical translation.
    Chen Y; Tandon I; Heelan W; Wang Y; Tang W; Hu Q
    Chem Soc Rev; 2022 Jul; 51(13):5330-5350. PubMed ID: 35713468
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Monitoring and deciphering protein degradation pathways inside cells.
    Daniels DL; Riching KM; Urh M
    Drug Discov Today Technol; 2019 Apr; 31():61-68. PubMed ID: 31200861
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Preclinical Studies of PROTACs in Hematological Malignancies.
    Fuchs O; Bokorova R
    Cardiovasc Hematol Disord Drug Targets; 2021; 21(1):7-22. PubMed ID: 33687890
    [TBL] [Abstract][Full Text] [Related]  

  • 31. PROTAC-DB: an online database of PROTACs.
    Weng G; Shen C; Cao D; Gao J; Dong X; He Q; Yang B; Li D; Wu J; Hou T
    Nucleic Acids Res; 2021 Jan; 49(D1):D1381-D1387. PubMed ID: 33010159
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Proteolysis-targeting chimeras: A promising technique in cancer therapy for gaining insights into tumor development.
    Lv M; Hu W; Zhang S; He L; Hu C; Yang S
    Cancer Lett; 2022 Jul; 539():215716. PubMed ID: 35500825
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Small molecule PROTACs: an emerging technology for targeted therapy in drug discovery.
    Pei H; Peng Y; Zhao Q; Chen Y
    RSC Adv; 2019 May; 9(30):16967-16976. PubMed ID: 35519875
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Development of Protein Knockdown Technology as Emerging Drug Discovery Strategy].
    Ohoka N
    Yakugaku Zasshi; 2018; 138(9):1135-1143. PubMed ID: 30175757
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Bridged Proteolysis Targeting Chimera (PROTAC) Enables Degradation of Undruggable Targets.
    Xiong Y; Zhong Y; Yim H; Yang X; Park KS; Xie L; Poulikakos PI; Han X; Xiong Y; Chen X; Liu J; Jin J
    J Am Chem Soc; 2022 Dec; 144(49):22622-22632. PubMed ID: 36448571
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Induced degradation of proteins by PROTACs and other strategies: towards promising drugs].
    Reboud-Ravaux M
    Biol Aujourdhui; 2021; 215(1-2):25-43. PubMed ID: 34397373
    [TBL] [Abstract][Full Text] [Related]  

  • 37. PROTACs: Novel approach for cancer breakdown by breaking proteins.
    Memon H; Patel BM
    Life Sci; 2022 Jul; 300():120577. PubMed ID: 35487303
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The application of ubiquitin ligases in the PROTAC drug design.
    Chen Y; Jin J
    Acta Biochim Biophys Sin (Shanghai); 2020 Jul; 52(7):776-790. PubMed ID: 32506133
    [TBL] [Abstract][Full Text] [Related]  

  • 39. PROTACs: Current Trends in Protein Degradation by Proteolysis-Targeting Chimeras.
    Madan J; Ahuja VK; Dua K; Samajdar S; Ramchandra M; Giri S
    BioDrugs; 2022 Sep; 36(5):609-623. PubMed ID: 36098871
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A beginner's guide to current synthetic linker strategies towards VHL-recruiting PROTACs.
    Zografou-Barredo NA; Hallatt AJ; Goujon-Ricci J; Cano C
    Bioorg Med Chem; 2023 Jun; 88-89():117334. PubMed ID: 37224698
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 65.